Skip to main content
Equibles
BBNX logo

BBNX · Beta Bionics, Inc. · Earnings Call Transcripts & Audio

Track BBNX — free

Use BBNX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BBNX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$16.57 -0.02 (-0.12%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$745.48M
Shares
44.99M

Beta Bionics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Beta Bionics, Inc. (BBNX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $20.44M −$18.11M '24 Q4 25-03-25 ▲36.4% $17.64M −$28.66M '25 Q1 25-05-06 ▲54.4% $23.24M −$16.87M '25 Q2 25-07-29 ▲63.1% $27.25M −$14.21M '25 Q3 25-10-28 ▲57.1% $32.12M −$13.47M '25 Q4 26-02-17 ▲56.6% $27.63M −$21.89M '26 Q1 26-04-21 LATEST ▲37.8% $32.01M −$23.40M '26 Q2 26-07-29
Earnings call
FY26 · Q2
2026-07-29
Beta Bionics, Inc. (BBNX) Q2 2026 Earnings Call
Revenue
$32.01M
▲ 37.8% YoY
Diluted EPS
$-0.53
Gross margin
59.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-21
Beta Bionics, Inc. (BBNX) Q1 2026 Earnings Call Transcript
Confident tone Revenue growth and new patient starts Gross margin improvement Full-year 2026 guidance raise
Revenue
$27.63M
▲ 56.6% YoY
Diluted EPS
$-0.49
Gross margin
59.5%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-17
Beta Bionics, Inc. (BBNX) Q4 2025 Earnings Call Transcript
Confident tone 2026 guidance and outlook Pharmacy channel strategy User growth and installed base
Revenue
$32.12M*
▲ 57.1% YoY
Gross margin
59.0%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Beta Bionics, Inc. (BBNX) Q3 2025 Earnings Call Transcript
Confident tone iLet commercial momentum FDA 483 / MAUDE reports Innovation pipeline (Mint and bihormonal)
Revenue
$27.25M
▲ 63.1% YoY
Diluted EPS
$-0.33
Gross margin
55.5%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Beta Bionics, Inc. (BBNX) Q2 2025 Earnings Call Transcript
Confident tone Pharmacy Channel Adoption iLet Product & Real-World Clinical Data Innovation Pipeline (Mint & Bihormonal)
Revenue
$23.24M
▲ 54.4% YoY
Diluted EPS
$-0.39
Gross margin
53.8%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Beta Bionics, Inc. (BBNX) Q1 2025 Earnings Call Transcript
Confident tone Q1 financial outperformance and raised 2025 guidance iLet product differentiation and algorithm Gross margin dynamics and near-term headwinds
Revenue
$17.64M
▲ 36.4% YoY
Diluted EPS
$-0.93
Gross margin
50.9%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-25
Beta Bionics, Inc. (BBNX) Q4 2024 Earnings Call
Revenue
$20.44M*
Gross margin
57.2%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–7 of 7 earnings calls
Key facts CIK 1674632 CUSIP 08659B102 13F (30d) 55 filings 55 filers Visit website Investor relations